On Wednesday, Keryx Biopharmaceuticals (NASDAQ:KERX) made the announcement that two major insurance providers added Auryxia, a drug used to control serum phosphorous levels in patients with …
In a research report issued June 22, Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Bioline RX Ltd (NASDAQ:BLRX) with a price …
Roth Capital analyst Joseph Pantginis offered commentary on Cytori Therapeutics Inc (NASDAQ:CYTX) after the company announced complete enrollment of its Phase II ACT-OA study which evaluates …
Sunesis Pharmaceuticals, Inc. (NASDAQ:SNSS) price target has been increased at Roth Caputal by research analyst Joseph Pantginis from $4.
Roth Capital analyst Joseph Pantginis offered commentary on Galena Biopharma Inc (NASDAQ:GALE) following the presentation of the Phase 2 clinical trial of GALE-401 at the …
Roth Capital analyst Joseph Pantginis weighed in with some commentary on Peregrine Pharmaceuticals (NASDAQ:PPHM) after the company generated a preclinical data set supporting the immune …
Roth Capital’s healthcare analyst Joseph Pantginis came out with a few insights on Celator Pharmaceuticals Inc (NASDAQ:CPXX), after the company announced enrollment completion of the supporting PK/PD …
Roth Capital analyst Joseph Pantginis weighed in with a few insights on Vascular Biogenics Ltd (NASDAQ:VBLT), after the Israeli biotech company presented updated data from its Phase …
The first quarter of 2015 has come to a close and companies are still releasing earnings reports. Let’s look back and see which …
Roth Capital analyst Joseph Pantginis reiterated a Buy rating on Celldex Therapeutics, Inc. (NASDAQ:CLDX) with a price target of $43, after the company announced the initiation …
